Home » Stocks » SUPN

Supernus Pharmaceuticals, Inc. (SUPN)

Stock Price: $30.96 USD 1.38 (4.67%)
Updated Feb 24, 2021 3:59 PM EST - Market closed
After-hours: $30.94 -0.02 (-0.07%) Feb 24, 4:09 PM
Market Cap 1.56B
Revenue (ttm) 477.29M
Net Income (ttm) 129.31M
Shares Out 52.66M
EPS (ttm) 2.41
PE Ratio 12.84
Forward PE 20.16
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $30.96
Previous Close $29.58
Change ($) 1.38
Change (%) 4.67%
Day's Open 29.72
Day's Range 29.72 - 31.26
Day's Volume 566,920
52-Week Range 13.12 - 31.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

ROCKVILLE, Md., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatmen...

GuruFocus - 1 month ago

If you pick securities whose earnings return is more than twice that of the 20-year high-quality market corporate bonds, you could increase your probability to unearth value opportunities, in ...

Other stocks mentioned: BIO, FVE
GlobeNewsWire - 1 month ago

ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...

Seeking Alpha - 1 month ago

It has been eight months since we last looked in on a promising biopharma concern named Supernus Pharmaceuticals. Some significant news has posted since then including some recently disclosed ...

The Motley Fool - 2 months ago

The company announced positive results from a clinical trial.

Schaeffers Research - 2 months ago

The shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) are up 17.7% at $26.50 at last check, after its experimental drug for attention deficit hyperactivity disorder (ADHD), SPN-812, met its...

Benzinga - 2 months ago

Supernus Pharmaceuticals Inc (NASDAQ: SUPN) announced Monday that its SPN-812 — a commercial treatment for patients with Attention Deficit Hyperactivity Disorder (ADHD), exhibited positive top...

Market Watch - 2 months ago

Supernus Pharmaceuticals Inc. shares jumped more than 20% in after-hours trading Tuesday after the company revealed positive results from a study of its potential drug for attention deficit hy...

GlobeNewsWire - 2 months ago

ROCKVILLE, Md., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...

Investopedia - 2 months ago

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: AMPH, AMRX, BIIB, HZNP, PAHC
Zacks Investment Research - 2 months ago

Let's see if Supernus Pharmaceuticals (SUPN) stock is a good choice for value-oriented investors right now from multiple angles.

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (“Supernus or the “Company”) (NASDAQ: SUPN). Such inv...

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $SUPN #classaction--The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN) ...

Business Wire - 3 months ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $SUPN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors

GlobeNewsWire - 3 months ago

ROCKVILLE, Md., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $SUPN #CLASSACTION--Glancy Prongay & Murray LLP, Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc (SUPN) on Behalf o...

GlobeNewsWire - 3 months ago

ROCKVILLE, Md., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...

PRNewsWire - 3 months ago

NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus or the "Company") (NASDAQ: SUPN). Such investo...

GlobeNewsWire - 3 months ago

ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...

Seeking Alpha - 3 months ago

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Supernus (SUPN) delivered earnings and revenue surprises of 174.07% and 18.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

ROCKVILLE, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...

GlobeNewsWire - 3 months ago

ROCKVILLE, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment o...

GuruFocus - 4 months ago

Investors who are looking for high return investments might be interested in the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt's method) a...

Other stocks mentioned: ENIA, TKC
GlobeNewsWire - 4 months ago

Greg Patrick to Retire as Chief Financial Officer Greg Patrick to Retire as Chief Financial Officer

Seeking Alpha - 4 months ago

Supernus is solidly on track for a new record of net sales this year and is still generating huge amounts of free cash flow.

The Motley Fool - 4 months ago

These stocks are just temporarily inconvenienced large caps in the making.

Other stocks mentioned: ADUS, INVA
Investopedia - 5 months ago

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: AZN, BIIB, MNTA, NLTX, PRGO, RLMD, SNY, TAK
GlobeNewsWire - 5 months ago

ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...

GlobeNewsWire - 5 months ago

ROCKVILLE, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...

GlobeNewsWire - 5 months ago

ROCKVILLE, Md., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...

Seeking Alpha - 6 months ago

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Supernus (SUPN) delivered earnings and revenue surprises of 85.71% and 0.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

ROCKVILLE, Md., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment...

GlobeNewsWire - 6 months ago

ROCKVILLE, Md., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment...

Zacks Investment Research - 6 months ago

Supernus (SUPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 6 months ago

Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research - 6 months ago

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 7 months ago

Gold, silver, miners/GSMs outperformed nicely in Q2, and should continue to do extremely well going forward.

Other stocks mentioned: AGI, BIDU, FSM, GDXJ, NOV, PAAS, SLB, TSLA
GlobeNewsWire - 7 months ago

ROCKVILLE, Md., June 26, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment...

InvestorPlace - 8 months ago

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

Other stocks mentioned: CORT, DVAX, GTHX, IMGN, KDMN, VRTX
GlobeNewsWire - 8 months ago

Creates leading CNS portfolio with five marketed products, two product candidates in late-stage development, and robust pipeline Creates leading CNS portfolio with five marketed products, two ...

Seeking Alpha - 8 months ago

Supernus Offers Strong Value In The CNS Space

GlobeNewsWire - 9 months ago

ROCKVILLE, Md., May 15, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment ...

Seeking Alpha - 9 months ago

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Supernus (SUPN) delivered earnings and revenue surprises of 33.33% and 11.47%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 9 months ago

A Super 'Pick-Up' By Supernus

GlobeNewsWire - 9 months ago

ROCKVILLE, Md., April 28, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatmen...

Zacks Investment Research - 9 months ago

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 10 months ago

These two underrated biotech stocks have the potential to soar.

Other stocks mentioned: KPTI

About SUPN

Supernus Pharmaceuticals, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in the United States. The company offers Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and in children 6 to 17 years of age; and Trokendi XR, an extended release topiramate, which is used for the prophylaxis of migraine headache, as well as for the treatment of epilepsy. Its prod... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
May 1, 2012
CEO
Jack Khattar
Employees
464
Stock Exchange
NASDAQ
Ticker Symbol
SUPN
Full Company Profile

Financial Performance

In 2019, SUPN's revenue was $392.76 million, a decrease of -3.95% compared to the previous year's $408.90 million. Earnings were $113.06 million, an increase of 1.86%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SUPN stock is "Buy." The 12-month stock price forecast is 31.00, which is an increase of 0.13% from the latest price.

Price Target
$31.00
(0.13% upside)
Analyst Consensus: Buy